BlackRock
CTKB icon

BlackRock’s Cytek Biosciences CTKB Stock Holding History

BlackRock’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$42.4M Sell
9,578,643
-7,428,626
-44% -$31.7M ﹤0.01% 2774
2026
Q1 		$74.3M Sell
17,007,269
-165,759
-1% -$783K ﹤0.01% 2285
2025
Q4 		$86.7M Buy
17,173,028
+625,335
+4% +$2.9M ﹤0.01% 2192
2025
Q3 		$57.4M Sell
16,547,693
-487,842
-3% -$1.83M ﹤0.01% 2419
2025
Q2 		$57.9M Sell
17,035,535
-1,033,747
-6% -$3.44M ﹤0.01% 2361
2025
Q1 		$72.5M Sell
18,069,282
-413,513
-2% -$2.14M ﹤0.01% 2183
2024
Q4 		$120M Sell
18,482,795
-9,496
-0.1% -$56.6K ﹤0.01% 1969
2024
Q3 		$102M Buy
18,492,291
+1,421,869
+8% +$8.06M ﹤0.01% 2073
2024
Q2 		$95.3M Sell
17,070,422
-355,549
-2% -$2.14M ﹤0.01% 2055
2024
Q1 		$117M Sell
17,425,971
-353,782
-2% -$2.8M ﹤0.01% 1966
2023
Q4 		$162M Buy
17,779,753
+1,009,080
+6% +$6.35M ﹤0.01% 1787
2023
Q3 		$92.6M Buy
16,770,673
+1,643,168
+11% +$13.2M ﹤0.01% 2036
2023
Q2 		$129M Buy
15,127,505
+6,840,258
+83% +$61.4M ﹤0.01% 1875
2023
Q1 		$76.2M Sell
8,287,247
-80,360
-1% -$864K ﹤0.01% 2188
2022
Q4 		$85.4M Buy
8,367,607
+449,965
+6% +$6.05M ﹤0.01% 2103
2022
Q3 		$117M Buy
7,917,642
+780,250
+11% +$10.1M ﹤0.01% 1863
2022
Q2 		$76.6M Buy
7,137,392
+1,044,052
+17% +$10.4M ﹤0.01% 2202
2022
Q1 		$65.7M Buy
6,093,340
+3,722,881
+157% +$50.3M ﹤0.01% 2413
2021
Q4 		$38.7M Buy
2,370,459
+515,716
+28% +$10.8M ﹤0.01% 2831
2021
Q3 		$39.7M Buy
+1,854,743
New +$43.6M ﹤0.01% 2812

Other funds holding CTKB

Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

BlackRock's CTKB Position: Q2 2026 in Review

BlackRock reduced its Cytek Biosciences (CTKB) stake by 44% in Q2 2026, selling an estimated $31.7M and leaving 9,578,643 shares worth $42.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2774.

BlackRock first reported a position in CTKB in Q3 2021 and has held it in 20 quarters since. The position peaked at $162M in Q4 2023. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • BlackRock held 9,578,643 shares of Cytek Biosciences worth $42.4M as of Q2 2026.
  • BlackRock sold 7,428,626 Cytek Biosciences shares in Q2 2026, an estimated $31.7M.
  • Cytek Biosciences made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #2774 holding.
  • BlackRock first reported a position in Cytek Biosciences in Q3 2021 and has held it in 20 quarters since.
  • BlackRock's Cytek Biosciences position peaked at $162M in Q4 2023.
  • 155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.